Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Core Insights - Actinium Pharmaceuticals is advancing Iomab-ACT, a targeted radiotherapy conditioning agent intended to replace traditional chemotherapy agents for CAR-T therapy, with initial clinical data expected in the second half of 2025 [1][2][3] - The Iomab-ACT trial aims to improve patient access and outcomes by reducing CAR-T related toxicities such as ICANS and CRS, which are significant barriers for patients [2][3] - The CAR-T therapy market generated over $4 billion in sales in 2024 and is projected to reach $12 billion by 2030, indicating a substantial market opportunity for Iomab-ACT [1][5] Company Developments - The first patient has been enrolled in the Iomab-ACT trial at the University of Texas Southwestern Medical Center, marking a significant step in the development of this innovative therapy [1][2] - Iomab-ACT targets CD45, selectively depleting immune cells associated with CAR-T toxicities while sparing essential blood components, which could lead to better patient outcomes [2][3] - Initial clinical results from a pilot study showed no patients developed ICANS and minimal CRS, supporting the advancement of Iomab-ACT into commercial trials [2][3] Market Opportunity - The addressable market for Iomab-ACT aligns with the approximately 150,000 patients annually who require conditioning for CAR-T therapies, suggesting a potential blockbuster revenue opportunity if clinical benefits are demonstrated [5] - The pipeline of CAR-T therapies is rapidly expanding, with the patient population expected to nearly double by 2030, further enhancing the market potential for Iomab-ACT [5]